文献速递外周动脉疾病

编辑精选——下肢外周动脉疾病血运重建患者的主要不良肢体事件:一项全国性观察性研究

Editor's Choice - Major Adverse Limb Events in Patients Undergoing Revascularisation for Lower Limb Peripheral Arterial Disease: A Nationwide Observational Study.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2024-08-08

基于瑞典国家血管外科登记处2008至2016年数据,纳入28021例下肢外周动脉疾病血运重建患者,其中间歇性跛行10506例(37.5%)、慢性肢体威胁性缺血17515例(62.5%)。平均随访3.2±2.4年,4分主要不良肢体事件(MALE)在间歇性跛行中1年发生率为21.4%(95%CI 20.6-22.2%),在慢性肢体威胁性缺血中为46.9%(95%CI 46.1-47.7%);慢性肾脏病和既往血运重建/截肢为调整后预测因素。

要点

  • 间歇性跛行患者1年4分MALE发生率为21.4%(95%CI 20.6-22.2%)。
  • 慢性肢体威胁性缺血患者1年4分MALE发生率为46.9%(95%CI 46.1-47.7%)。
  • 慢性肾脏病在间歇性跛行(HR 1.33)和慢性肢体威胁性缺血(HR 1.25)中均为调整后预测因素。

核心结论

  • 血运重建后的下肢外周动脉疾病患者MALE发生率非常高,尤其是慢性肢体威胁性缺血患者。
  • 间歇性跛行患者既往下肢血运重建与MALE发生率升高相关,慢性肢体威胁性缺血患者既往下肢截肢与后续MALE相关。
  • 无论采用何种MALE定义,慢性肾脏病在间歇性跛行和慢性肢体威胁性缺血中均与较差结局相关。

研究设计与样本

  • 基于合并国家登记数据的 population based 观察性研究。
  • 从瑞典国家血管外科登记处检索2008至2016年间接受下肢血运重建的下肢外周动脉疾病患者。
  • 共分析28021例血运重建患者,其中间歇性跛行10506例(37.5%),慢性肢体威胁性缺血17515例(62.5%)。
  • 间歇性跛行和慢性肢体威胁性缺血患者分别使用Kaplan-Meier估计进行分析,采用逐步Cox比例风险模型进行预测因素分析。

主要发现

  • 平均随访3.2±2.4年期间,发生2分、3分和4分MALE的患者分别为5226例(18.7%)、9423例(33.6%)和12696例(45.3%)。
  • 估计1年4分MALE发生率在间歇性跛行为21.4%(95%CI 20.6-22.2%),在慢性肢体威胁性缺血为46.9%(95%CI 46.1-47.7%)。
  • 间歇性跛行中4分MALE的调整后预测因素包括慢性肾脏病(HR 1.33,95%CI 1.12-1.59)和既往下肢血运重建(HR 1.29,95%CI 1.19-1.40)。
  • 慢性肢体威胁性缺血中4分MALE的调整后预测因素包括既往对侧下肢截肢(HR 1.60,95%CI 1.47-1.73)和慢性肾脏病(HR 1.25,95%CI 1.17-1.34)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Major adverse limb events (MALEs) are frequent in patients with lower extremity peripheral arterial disease (PAD). However, routine care MALE rate estimations after revascularisation are scarce. This study aimed to determine post-procedural MALE rates in revascularised patients with PAD and identify predictors of post-procedural MALEs. METHODS: This was a population based observational study on merged national registry data. Patients with PAD undergoing lower limb revascularisation between 2008 and 2016 were retrieved from the Swedish National Registry for Vascular Surgery. Information on comorbidities, medications, and post-procedural MALE endpoints were identified in national healthcare registries. Primary outcomes of interest were categorised as 2 - 4 point MALE composites that included limb amputation, acute lower limb ischaemia, progression to or relapse of chronic limb threatening ischaemia (CLTI), and ipsilateral re-interventions regardless of indication. Patients with intermittent claudication (IC) and CLTI were analysed separately using Kaplan-Meier estimates. Stepwise Cox proportional hazard models were used for predictor candidate analysis. RESULTS: Overall, 28 021 revascularised patients with PAD were analysed (IC, n = 10 506, 37.5%; CLTI, n = 17 515, 62.5%). During a mean follow up ± standard deviation of 3.2 ± 2.4 years, 5 226 (18.7%), 9 423 (33.6%), and 12 696 (45.3%) patients experienced a 2, 3, and 4 point MALE, respectively. The estimated one year 4 point MALE rates were 21.4% (95% confidence interval [CI] 20.6 - 22.2%) in IC and 46.9% (95% CI 46.1 - 47.7%) in CLTI. Adjusted predictors for experiencing a 4 point MALE in IC were chronic kidney disease (CKD) (hazard ratio [HR] 1.33, 95% CI 1.12 - 1.59) and previous lower limb revascularisation (HR 1.29, 95% CI 1.19 - 1.40). In CLTI, previous contralateral lower limb amputation (HR 1.60, 95% CI 1.47 - 1.73) and CKD (HR 1.25, 95% CI 1.17 - 1.34) were adjusted predictors. CONCLUSION: This study emphasises the very high MALE rates in revascularised patients with lower limb PAD, especially in CLTI. Prior lower limb revascularisation correlated with increased MALE rates in IC patients, while prior lower limb amputation was linked to subsequent MALEs in CLTI. In both IC and CLTI, CKD was associated with poorer outcomes, regardless of applied MALE definition.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Amlani V, Ludwigs K, Rawshani A, et al. Editor's Choice - Major Adverse Limb Events in Patients Undergoing Revascularisation for Lower Limb Peripheral Arterial Disease: A Nationwide Observational Study. Eur J Vasc Endovasc Surg. 2024. PMID: 39121905. doi:10.1016/j.ejvs.2024.07.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。